On July 29, Guolonghui reported that Jpmorgan has raised its target price for the joint treatment company from $300 to $360.
小摩上调联合治疗目标价至360美元
Morgan Stanley raised the target price for combination therapy to $360.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated